Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Depreciation & Amortization (CF) (2016 - 2025)

Lisata Therapeutics' Depreciation & Amortization (CF) history spans 13 years, with the latest figure at -$31000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 146.27% year-over-year to -$31000.0; the TTM value through Dec 2025 reached $100000.0, down 50.0%, while the annual FY2025 figure was $100000.0, 50.0% down from the prior year.
  • Depreciation & Amortization (CF) reached -$31000.0 in Q4 2025 per LSTA's latest filing, down from $44000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $67000.0 in Q4 2024 to a low of -$31000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 3 years is $41666.7, with a median of $45500.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 15.52% in 2024, then tumbled 146.27% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $58000.0 in 2023, then rose by 15.52% to $67000.0 in 2024, then plummeted by 146.27% to -$31000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Depreciation & Amortization (CF) are -$31000.0 (Q4 2025), $44000.0 (Q3 2025), and $44000.0 (Q2 2025).